

Cobimetinib

Catalog No: tcsc0521

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:

934660-93-2

Formula:

 $\mathsf{C}_{21}\mathsf{H}_{21}\mathsf{F}_3\mathsf{IN}_3\mathsf{O}_2$

Pathway: MAPK/ERK Pathway

Target:

MEK

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 100 mg/mL (188.21 mM)

Alternative Names:

GDC-0973;XL518

Observed Molecular Weight:

531.31

Copyright 2021 Taiclone Biotech Corp.




Product Description

Cobimetinib is a novel selective **MEK** inhibitor, and the **IC₅₀** value against MEK1 is 4.2 nM.

IC50 & Target: IC50: 4.2 nM (MEK1)

In Vitro: The EC₅₀ values of Cobimetinib (GDC-0973) for 888MEL and A2058 cells are 0.2 μ M, 10 μ M, respectivelly. Melanoma cells are treated with EC₅₀ concentration of MEK and PI3K inhibitors for 24 hours (888MEL: 0.05 μ M GDC-0973, 2.5 μ M GDC-0941; A2058: 2.5 μ M GDC-0973, 2.5 μ M GDC-0941)^[1]. Mitochondrial OXPHOS limits cell death induced by cobimetinib (100 nM) in melanoma with constitutive MAPK activation in A375 cells^[4].

In Vivo: In the NCI-H2122 KRASG12C mutant non-small cell lung carcinoma (NSCLC) xenograft model, treatment with up to 5 mg/kg Cobimetinib (GDC-0973) lead to moderate TGI and at 10 mg/kg approaches tumor stasis^[1]. GDC-0973 and GDC-0941 are administered to A2058 tumor-bearing mice daily (QD) or every third day (Q3D) either as single agents or in combination. The population rate constants associated with tumor growth inhibition for GDC-0973 and GDC-0941 are 0.00102 and 0000651 μ M⁻¹ h⁻¹, respectively^[2]. Following single doses of GDC-0973 (1, 3, or 10 mg/kg, p.o.) estimated in vivo IC₅₀ values of %pERK decrease based on tumor concentrations in xenograft mice are 0.78 (WM-266-4) and 0.52 μ M (A375)^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.